Mean Short-Form 36 (SF-36) domain scores at baseline and 6 months in patients receiving active or placebo corticosteroids, cDMARDs or TNFis. Mean Short-Form.

Slides:

Advertisements

Similar presentations

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Quality of Life After Treatment of Laryngeal.

Advertisements

Triangles and dotted lines are for mean values. , P <

Immunohistochemical (IHC) staining for CD68/CD21 and CD3/CD20 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral.

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Mean changes in the Short Form-36 subscales from baseline values for combined pulmonary fibrosis and emphysema (CPFE) (n=16), and chronic obstructive pulmonary.

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Clinical Epidemiology and Global Health

Health-Related Quality-of-Life Measures: Evidence from Tunisian Population Using the SF-12 Health Survey Moheddine Younsi, PhD Value in Health Regional.

Volume 61, Issue 5, Pages (November 2014)

The Impact of Pain Management on Quality of Life

Five-year real world outcomes of GeoForm ring implantation in patients with ischemic mitral regurgitation Tomasz A. Timek, MD, Robert L. Hooker, MD,

Effects of deep hypothermic circulatory arrest on outcome after resection of ascending aortic aneurysm Franz F Immer, MD, Hanna Barmettler, MD, Pascal.

Immunohistochemical (IHC) staining for CD117 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis.

Health-Related Quality of Life Outcome After On-Pump Versus Off-Pump Coronary Artery Bypass Graft Surgery: A Prospective Randomized Study Reza Motallebzadeh,

Responsiveness and clinically important differences for the WOMAC and SF-36 after hip joint replacement J.M. Quintana, Ph.D., A. Escobar, M.D., A. Bilbao,

Responsiveness and clinically important differences for the WOMAC and SF-36 after total knee replacement A. Escobar, M.D., J.M. Quintana, Ph.D., A. Bilbao,

Quantity of clot lysed after catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with postthrombotic morbidity Nina K. Grewal,

Long-Term Health-Related Quality of Life After Maze Surgery for Atrial Fibrillation Catharina Lundberg, MD, Anders Albåge, MD, PhD, Carina Carnlöf, RN,

Comparison of recovery after mitral valve repair and replacement

Mu Qin et al. JACEP 2017;j.jacep

(A) Quality of life scores in individuals with and without constipation. (A) Quality of life scores in individuals with and without constipation. (B) Quality.

Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.

Clinical Epidemiology and Global Health

Mean change from baseline in disease and disability outcomes at 6 months for TNFi initiators by anti-CCP status. Mean change from baseline in disease and.

Health-related quality of life in survivors of open ruptured abdominal aortic aneurysm repair: A matched, controlled cohort study Andrew B. Hill, MDCM,

Seth D. Crockett, Quinn K. Lippmann, Evan S. Dellon, Nicholas J

HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.

ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Relationships between the baseline disease activity scores and scintigraphic sum scores for the patients with RA, pSpA and axSpA. Relationships between.

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

Column bar graphs showing Health Assessment Questionnaire (HAQ) scores and pain score on Visual Analogue Scale (VAS) (scale 0–10) that were collected at.

Independent baseline predictors of non-remission at 24 months of follow-up in the SWEFOT trial population. Independent baseline predictors of non-remission.

SF-36 domain scores at baseline and 24 weeks compared with age-matched and gender-matched normative values in the (A) AMBITION and (B) ADACTA trial populations.

Prescription rates of (A) NSAIDs, glucocorticoids and analgaesics, (B) TNF inhibitors and synthetic DMARDs and (C) combination therapy of NSAIDs with TNF.

Low-dose glucocorticoid chronotherapy in rheumatoid arthritis (RA) include the night-time-release prednisone, a timing drug release formulation with administration.

Mean individual and summative SF-36 V2 scores before and 3 months after ablation. Mean individual and summative SF-36 V2 scores before and 3 months after.

Difference in the risk of MACEs in patients treated with anti–IL17 agents compared with the placebo in RCTs. IL,interleukin; MACEs, major adverse cardiovascular.

Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Patient-reported adherence towards different IMID treatments.

Clinical response in patients with early and established RA at month 24. *p

Patient-reported quality of life after abdominal aortic aneurysm surgery: A prospective comparison of endovascular and open repair Badr Aljabri, MD,

Relative impact of the different levels of education on the physical and mental components of SF-12 across the different chronic disorders. Relative impact.

Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,

Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

Improvement in FACIT-F fatigue score according to ACR20 response status (ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic.

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

Spydergram of mean SF-36 domain scores at baseline and weeks 12 (A) and 24 (B) for sarilumab 150 mg and 200 mg+csDMARDs compared with placebo+csDMARDs.

Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment Ralf W. Sprengers, MD, Martin Teraa,

Spider plot of the unstandardised SF-36v2 subscales, comparing our HCM population with the mean for the general population (aged 45–54 years). Spider plot.

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

Ultrasonographic characteristics and synovitis pattern of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis under tumour.

Efficacy as first, second and third bDMARD in patients with axial spondyloarthritis. ASAS, Assessment of Spondylo Arthritis international Society; BASDAI,

Quality of life after aortic valve replacement with tissue and mechanical implants Artyom Sedrakyan, MD, Patricia Hebert, PhD, Viola Vaccarino, MD, PhD,

J. J. Smith, FRCS, A. M. Garratt, PhD, M. Guest, FRCS, R. M

Proportion of patients reporting improvements from baseline in patient-reported outcomes (PROs) ≥ the MCID at (A) 16 weeks in OPTION, (B) 12 weeks in BREVACTA.

Study design. *Randomisation stratified by corticosteroid use at baseline. Study design. *Randomisation stratified by corticosteroid use at baseline. DAS28-CRP,

Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;

Satisfaction with control of RA

SIR data for all CZP-treated patients (RCT+OLE) for each malignancy type, standardised to the general population by age and gender (GLOBOCAN and SEER).

Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.

DAPSA LSM change from baseline (A), patients achieving DAPSA ≤28 (MDA) (B), DAPSA ≤14 (LDA) (C) or DAPSA ≤4 (REM) (D) after 24 weeks in patients treated.

LPA groups display vastly different outcomes.

Systematic review and network meta-analyses study selection flow chart

Joint pain location and severity.

Multivariable model of adjusted

ACPA and RF titres in patients with early RA treated with abatacept+MTX compared with MTX alone. ACPA and RF titres in patients with early RA treated with.

Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from.

ACR20 (A), ACR50 (B) and MDA (C) response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or when added to background cDMARDs or.

Presentation transcript:

Mean Short-Form 36 (SF-36) domain scores at baseline and 6 months in patients receiving active or placebo corticosteroids, cDMARDs or TNFis. Mean Short-Form 36 (SF-36) domain scores at baseline and 6 months in patients receiving active or placebo corticosteroids, cDMARDs or TNFis. (A) Patients with early RA in the CARDERA trial randomised to receive either active or placebo high-dose tapering corticosteroids (baseline placebo and 6 months placebo=mean SF-36 domain scores at 0 and 6 months in patients receiving placebo corticosteroids; baseline active and 6 months active=mean SF-36 domain scores at 0 and 6 months in patients receiving active corticosteroids; A/G norms=mean SF-36 domain scores in an age-matched and gender-matched normative US population). (B) Patients with established RA in the TACIT trial randomised to receive either cDMARD or TNFi (baseline cDMARD and 6 months cDMARD=mean SF-36 domain scores at 0 and 6 months in patients receiving cDMARDs; baseline TNFi and 6 months TNFi=mean SF-36 domain scores at 0 and 6 months in patients receiving TNFi; A/G norms=mean SF-36 domain scores in an age-matched and gender-matched normative US population). BP, bodily pain; cDMARD, combination disease-modifying antirheumatic drug; GH, general health; MH, mental health; PF, physical functioning; RA, rheumatoid arthritis; RE, role emotional; RP, role physical; SF, social functioning; TNFi, tumour necrosis factor-α inhibitor; VT, vitality. I C Scott et al. RMD Open 2016;2:e000270 Copyright © BMJ Publishing Group & EULAR. All rights reserved.